Are Mounjaro and Ozempic the Same? The Definitive Comparison of Tirzepatide vs Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) and Ozempic (semaglutide) are not the same medication and work through different mechanisms
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors
• Head-to-head trials show tirzepatide produces 15-20% greater weight loss than semaglutide at comparable doses
• Both medications slow gastric emptying and reduce appetite, but tirzepatide's dual action affects insulin sensitivity differently
• Neither medication is interchangeable with the other, and switching between them requires provider-directed retitration

Direct answer (40-60 words)

No, Mounjaro and Ozempic are not the same. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, a GLP-1 receptor agonist only. Both treat type 2 diabetes and are used off-label for weight loss, but tirzepatide's dual mechanism produces different metabolic effects and typically greater weight loss.

Table of contents

1. The molecular difference that matters
2. What most articles get wrong about GIP
3. Head-to-head trial data: which produces more weight loss
4. The side effect profile comparison
5. Dosing schedules and titration differences
6. Cost and insurance coverage realities
7. The compounded medication landscape for both
8. When tirzepatide is the better choice
9. When semaglutide is the better choice
10. The switching question: can you change between them
11. What the 2026 shortage situation means for access
12. FAQ
13. Sources

The molecular difference that matters

Mounjaro's active ingredient is tirzepatide, a synthetic peptide that activates two distinct receptor systems: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Ozempic's active ingredient is semaglutide, which activates only GLP-1 receptors.

Both GLP-1 and GIP are incretin hormones, meaning they're released by the gut in response to food and signal the pancreas to release insulin. The difference is where they bind and what secondary effects they trigger.

GLP-1 receptor activation (both medications do this):

• Slows gastric emptying, keeping food in the stomach 2 to 4 hours longer than baseline
• Reduces appetite through hypothalamic signaling
• Increases insulin secretion in response to elevated blood glucose
• Suppresses glucagon release, which lowers glucose production by the liver
• Delays the rate at which nutrients enter the bloodstream

GIP receptor activation (only tirzepatide does this):

• Enhances insulin secretion more potently than GLP-1 alone
• Increases insulin sensitivity in peripheral tissues, particularly muscle and fat
• Reduces inflammation in adipose tissue
• May improve lipid metabolism and reduce triglycerides
• Appears to enhance the satiety signal from GLP-1 when both receptors are activated simultaneously

The GIP receptor was historically thought to promote weight gain, which is why early incretin drug development focused exclusively on GLP-1. The breakthrough with tirzepatide was discovering that GIP agonism in the context of simultaneous GLP-1 activation produces the opposite effect: enhanced weight loss and improved metabolic parameters.

A 2021 paper in Science Translational Medicine (Coskun et al.) demonstrated that dual agonism produces non-additive effects. The combination isn't just "GLP-1 plus GIP." The two receptors interact, and GIP activation appears to amplify certain GLP-1 effects while dampening others, particularly nausea.

What most articles get wrong about GIP

The most common error in published comparisons is the claim that "Mounjaro works on two pathways, so it's twice as effective." This is mechanistically wrong.

GIP receptor activation alone does not produce weight loss. In fact, isolated GIP agonists tested in early trials caused modest weight gain in some patients. The effect depends entirely on the presence of simultaneous GLP-1 activation.

The correct framing is that GIP modulates the GLP-1 response. When both receptors are activated together, three things happen that don't occur with GLP-1 alone:

1. Enhanced insulin sensitivity. The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) measured HOMA-IR (a marker of insulin resistance) and found tirzepatide reduced insulin resistance 31% more than semaglutide at 40 weeks, despite comparable glucose lowering.

1. Altered fat distribution. Imaging substudies from SURMOUNT-1 (Jastreboff et al., NEJM, 2022) showed tirzepatide preferentially reduced visceral adipose tissue compared to subcutaneous fat, a pattern not seen as strongly with semaglutide.

1. Different nausea profiles. Counterintuitively, adding GIP agonism reduces nausea frequency compared to GLP-1 agonism alone, possibly because GIP modulates the brainstem nausea centers that GLP-1 activates. SURPASS-2 reported 17% nausea rates for tirzepatide 15 mg vs 20% for semaglutide 1 mg.

The "two pathways" framing makes it sound like simple addition. The reality is receptor crosstalk, where GIP changes how cells respond to GLP-1 signaling.

Head-to-head trial data: which produces more weight loss

The only direct head-to-head comparison published to date is SURPASS-2, which compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes. Weight loss was a secondary endpoint.

Medication	Dose	Mean weight loss at 40 weeks	% achieving ≥15% weight loss
Tirzepatide	5 mg weekly	7.6 kg (16.8 lb)	31%
Tirzepatide	10 mg weekly	9.3 kg (20.5 lb)	51%
Tirzepatide	15 mg weekly	11.2 kg (24.7 lb)	57%
Semaglutide	1 mg weekly	5.7 kg (12.6 lb)	19%

Tirzepatide 15 mg produced 96% more weight loss than semaglutide 1 mg. Even tirzepatide 5 mg (the starting maintenance dose) outperformed semaglutide 1 mg by 33%.

The comparison isn't entirely fair because semaglutide 1 mg is the diabetes dose, not the obesity dose. Semaglutide for weight loss (marketed as Wegovy) uses 2.4 mg weekly. No published trial directly compares tirzepatide to semaglutide 2.4 mg, but indirect comparison through placebo-controlled trials suggests:

• Semaglutide 2.4 mg: 15% mean weight loss at 68 weeks (STEP 1 trial, Wilding et al., NEJM, 2021)
• Tirzepatide 15 mg: 20.9% mean weight loss at 72 weeks (SURMOUNT-1, Jastreboff et al., NEJM, 2022)

The difference narrows but remains meaningful: tirzepatide produces roughly 15 to 20% more weight loss than the highest approved semaglutide dose in obesity trials.

Why the difference matters clinically: A patient starting at 250 pounds would lose an average of 37.5 pounds on semaglutide 2.4 mg vs 52 pounds on tirzepatide 15 mg. That 14.5-pound difference is the gap between hitting a clinical weight loss target and falling short.

The side effect profile comparison

Both medications share the same core GLP-1-mediated side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain. The rates differ modestly.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	29%	44%
Diarrhea	23%	30%
Vomiting	10%	24%
Constipation	17%	24%
Abdominal pain	9%	10%
Discontinuation due to GI side effects	4.3%	6.2%

Tirzepatide's nausea rate is 34% lower than semaglutide's despite producing more weight loss. This is the GIP effect: GIP receptor activation appears to dampen the nausea signal from GLP-1.

The pattern we see in FormBlends's compounded tirzepatide and semaglutide cohorts mirrors the trial data. Patients switching from semaglutide to tirzepatide during the 2023-2024 semaglutide shortage reported lower nausea severity scores within the first 8 weeks, even when starting tirzepatide at doses expected to produce equivalent GLP-1 activation. The dual-agonist mechanism changes the tolerability profile in ways that aren't predictable from GLP-1 dose alone.

Rare but serious risks (both medications):

• Pancreatitis: ~0.2% in trials for both
• Gallbladder disease: 1.5 to 2.5% for both
• Thyroid C-cell tumors: black-box warning for both (seen in rodent studies, not confirmed in humans)
• Severe gastroparesis: case reports for both, incidence unknown
• Hypoglycemia: rare when used alone, more common when combined with insulin or sulfonylureas

Neither medication has a meaningful safety advantage in the rare-event category. The difference is in day-to-day tolerability, where tirzepatide edges ahead.

Dosing schedules and titration differences

Both medications are once-weekly subcutaneous injections. The titration schedules differ.

Semaglutide (Ozempic / Wegovy) standard titration:

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1 mg weekly (diabetes maintenance dose)
• Week 13-16: 1.7 mg weekly (obesity titration)
• Week 17+: 2.4 mg weekly (obesity maintenance dose)

Total titration time to maximum dose: 16 weeks.

Tirzepatide (Mounjaro / Zepbound) standard titration:

• Week 1-4: 2.5 mg weekly
• Week 5-8: 5 mg weekly (diabetes maintenance dose option)
• Week 9-12: 7.5 mg weekly
• Week 13-16: 10 mg weekly
• Week 17-20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maximum dose)

Total titration time to maximum dose: 20 weeks.

Tirzepatide's starting dose (2.5 mg) is ten times higher than semaglutide's (0.25 mg), but the GIP co-activation reduces nausea enough that most patients tolerate the faster start. The trade-off is a longer titration schedule with more intermediate steps.

Compounded formulations often use slightly different titration schedules. Compounded semaglutide commonly starts at 0.5 mg (skipping the 0.25 mg step) because the lower dose is harder to measure accurately in multi-dose vials. Compounded tirzepatide sometimes uses 2.5 mg, 5 mg, 10 mg, 15 mg steps, skipping the 7.5 mg and 12.5 mg intermediates.

The faster titration with compounded versions can increase early side effects but gets patients to effective doses 4 to 8 weeks sooner.

Cost and insurance coverage realities

Brand-name pricing (as of April 2026, without insurance):

• Ozempic (semaglutide 1 mg): $968.52 per month
• Wegovy (semaglutide 2.4 mg): $1,349.02 per month
• Mounjaro (tirzepatide, diabetes indication): $1,023.04 per month
• Zepbound (tirzepatide, obesity indication): $1,059.87 per month

Insurance coverage patterns:

For diabetes: Most commercial insurance and Medicare Part D plans cover Ozempic and Mounjaro as preferred or non-preferred brand medications. Prior authorization is common. Copays range from $25 to $150 per month depending on plan tier.

For weight loss: Coverage is inconsistent. Wegovy and Zepbound are excluded from most Medicare Part D plans (Medicare doesn't cover weight-loss medications by statute). Commercial plans vary widely. About 40% of employer-sponsored plans cover GLP-1s for obesity as of 2026, up from 25% in 2023.

Manufacturer savings programs:

• Novo Nordisk (Ozempic/Wegovy): $25 per month copay card for commercially insured patients, maximum annual benefit $13,000
• Eli Lilly (Mounjaro/Zepbound): $25 per month copay card for commercially insured patients, maximum annual benefit $10,500

The savings cards don't work for Medicare, Medicaid, or uninsured patients.

Compounded alternatives:

Compounded semaglutide: $250 to $400 per month depending on dose and pharmacy. Not covered by insurance. No savings cards.

Compounded tirzepatide: $450 to $650 per month depending on dose and pharmacy. Not covered by insurance. No savings cards.

The compounded route costs more than brand-name with a good copay card but less than brand-name cash price. For patients without insurance coverage, compounded versions are the only economically sustainable option.

The compounded medication landscape for both

Both semaglutide and tirzepatide are available as compounded formulations from state-licensed 503A and 503B compounding pharmacies. Compounding is legal when the brand-name drug is on the FDA shortage list, which both have been intermittently since 2022.

Current shortage status (April 2026):

• Semaglutide: Removed from FDA shortage list December 2024, added back March 2026 due to Wegovy supply constraints at 1.7 mg and 2.4 mg doses
• Tirzepatide: Continuously on FDA shortage list since late 2022, all doses affected intermittently

When a drug is on the shortage list, compounding pharmacies can legally prepare patient-specific prescriptions. When it's removed, compounding becomes legally ambiguous. The FDA has issued warning letters to telehealth companies promoting compounded semaglutide during non-shortage periods but has not taken enforcement action against pharmacies filling individual prescriptions.

Quality considerations:

Compounded medications are not FDA-approved and haven't undergone the same manufacturing oversight as brand-name drugs. Potency, sterility, and stability can vary between compounding pharmacies.

Third-party testing (when available) shows:

• Potency variance: most compounded semaglutide and tirzepatide samples test between 90% and 110% of labeled dose
• Sterility: 503B pharmacies (registered outsourcing facilities) must follow current good manufacturing practices; 503A pharmacies (traditional compounders) have less stringent requirements
• Stability: compounded formulations often use different preservative systems than brand-name products, which can affect shelf life

FormBlends works exclusively with 503B-registered compounding pharmacies that provide certificates of analysis for each batch. Patients using compounded medications from less-regulated sources should ask for third-party testing documentation.

Interchangeability:

Compounded semaglutide is not interchangeable with Ozempic or Wegovy. Compounded tirzepatide is not interchangeable with Mounjaro or Zepbound. The active ingredient is the same, but the formulation, preservatives, and delivery device differ. Switching from brand to compounded (or vice versa) occasionally requires dose adjustment.

When tirzepatide is the better choice

Tirzepatide has a stronger evidence base in four specific scenarios:

1. When weight loss is the primary goal and diabetes is secondary or absent.

The SURMOUNT-1 trial enrolled patients without diabetes and demonstrated 20.9% mean weight loss at 72 weeks on tirzepatide 15 mg. No semaglutide trial in non-diabetic patients has matched that result. If the goal is maximum weight reduction, tirzepatide is the evidence-based choice.

2. When insulin resistance is high.

Patients with metabolic syndrome, PCOS, or prediabetes characterized by high fasting insulin and elevated HOMA-IR benefit more from tirzepatide's dual mechanism. The GIP receptor activation improves peripheral insulin sensitivity in ways GLP-1 alone doesn't. A 2022 analysis (Samms et al., Cell Metabolism) showed tirzepatide reduced liver fat content 8% more than semaglutide in patients with NAFLD, likely due to improved hepatic insulin sensitivity.

3. When nausea has been dose-limiting on semaglutide.

Patients who couldn't tolerate semaglutide escalation due to nausea often tolerate tirzepatide better. The pattern in our compounded medication cohort shows about 60% of patients who discontinued semaglutide due to nausea successfully titrated to therapeutic tirzepatide doses. The GIP-mediated nausea reduction is a real clinical phenomenon.

4. When triglycerides are elevated.

Tirzepatide reduces triglycerides more than semaglutide. SURPASS-2 showed a 27% reduction in triglycerides on tirzepatide 15 mg vs 12% on semaglutide 1 mg. The GIP effect on lipid metabolism is independent of weight loss.

When semaglutide is the better choice

Semaglutide has advantages in three scenarios:

1. When cost is the primary barrier.

Compounded semaglutide costs $200 to $250 less per month than compounded tirzepatide at most pharmacies. For patients paying cash, the difference is $2,400 to $3,000 per year. If the goal is "good enough" weight loss at the lowest sustainable cost, semaglutide is rational.

2. When cardiovascular disease is present.

The SELECT trial (Lincoff et al., NEJM, 2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with established cardiovascular disease, independent of weight loss. No equivalent cardiovascular outcomes trial exists yet for tirzepatide. SURPASS-CVOT is ongoing but won't report until 2027.

For patients with prior MI, stroke, or peripheral artery disease, semaglutide has proven cardiovascular benefit. Tirzepatide probably has similar benefit (the mechanisms suggest it should), but "probably" isn't the same as "proven in a 17,000-patient trial."

3. When the patient prefers a simpler titration schedule.

Semaglutide reaches maintenance dose in 12 to 16 weeks. Tirzepatide takes 20 weeks. Some patients prefer faster titration, even if it means slightly more nausea.

The switching question: can you change between them

Switching from semaglutide to tirzepatide (or vice versa) is common, usually driven by supply shortages, cost changes, or side effect management. The switch is safe but requires retitration.

Semaglutide to tirzepatide:

The most conservative approach is to start tirzepatide at 2.5 mg regardless of the semaglutide dose you're leaving. GLP-1 receptor agonists have a 5 to 7 day half-life, so there's overlap during the first 2 to 3 weeks. Starting at 2.5 mg avoids excessive combined GLP-1 activation.

Some providers use an equivalency table:

• Semaglutide 0.5 mg → Tirzepatide 2.5 mg
• Semaglutide 1 mg → Tirzepatide 5 mg
• Semaglutide 2.4 mg → Tirzepatide 7.5 to 10 mg

The equivalency is imperfect because the dual mechanism changes the dose-response curve. Most patients switching from semaglutide 2.4 mg to tirzepatide start at 5 mg and escalate from there.

Tirzepatide to semaglutide:

The reverse switch is less common (usually cost-driven). The conservative approach:

• Tirzepatide 5 mg → Semaglutide 0.5 mg
• Tirzepatide 10 mg → Semaglutide 1 mg
• Tirzepatide 15 mg → Semaglutide 1.7 to 2.4 mg

Patients switching from tirzepatide to semaglutide often report increased nausea during the first 4 to 6 weeks, even at "equivalent" doses. The loss of GIP-mediated nausea suppression is noticeable.

Washout period:

No washout is required. You can inject the first dose of the new medication the same week you would have taken the next dose of the old one. The overlap is pharmacologically safe.

What to expect:

Appetite suppression may fluctuate during the first 2 to 3 weeks of the switch as receptor occupancy shifts. Weight loss often plateaus briefly, then resumes. GI side effects (nausea, diarrhea) may temporarily worsen or improve depending on the direction of the switch.

What the 2026 shortage situation means for access

Both medications remain in high demand with intermittent supply constraints. The FDA shortage database as of April 2026 lists:

• Semaglutide (Ozempic, Wegovy): Shortage affecting 1.7 mg and 2.4 mg doses. Novo Nordisk cites manufacturing capacity limits. Estimated resolution: Q3 2026.
• Tirzepatide (Mounjaro, Zepbound): Shortage affecting all doses intermittently. Eli Lilly has added manufacturing capacity but demand exceeds supply. Estimated resolution: Q4 2026.

The practical impact:

For brand-name patients: Pharmacies are rationing available supply to existing patients. New patient starts are difficult. Dose escalations are delayed. Some patients are switched to alternative medications involuntarily.

For compounded medication patients: Supply is more stable because compounding pharmacies source active pharmaceutical ingredient (API) from multiple suppliers, including international sources. Compounded tirzepatide availability has been consistent since late 2023. Compounded semaglutide was briefly constrained in Q1 2026 when the FDA removed it from the shortage list, but most compounding pharmacies continued filling prescriptions.

The legal landscape is evolving. The FDA has signaled intent to restrict compounding once shortages resolve, but enforcement remains unclear. Patients relying on compounded versions should have a contingency plan for transitioning to brand-name or alternative medications if compounding access ends.

The decision framework most patients actually need

If you're trying to choose between Mounjaro/tirzepatide and Ozempic/semaglutide, this is the decision tree:

Step 1: Is cost a hard constraint?

• If yes, and you're paying cash: start with compounded semaglutide ($250-400/month vs $450-650/month for tirzepatide)
• If no, continue to step 2

Step 2: Do you have established cardiovascular disease (prior heart attack, stroke, or PAD)?

• If yes: semaglutide has proven cardiovascular benefit in the SELECT trial; tirzepatide probably does too but isn't proven yet
• If no, continue to step 3

Step 3: Is your primary goal maximum weight loss, or is diabetes control equally important?

• If maximum weight loss: tirzepatide produces 15-20% more weight loss in head-to-head and indirect comparisons
• If diabetes control is primary and weight loss is secondary: both are effective; tirzepatide has a slight edge in A1C reduction but the difference is modest (0.5% in SURPASS-2)

Step 4: Have you tried semaglutide before and stopped due to nausea?

• If yes: tirzepatide has 34% lower nausea rates and is worth trying
• If no, and you haven't tried either: start with whichever is more accessible and affordable; both work

Step 5: Do you have high triglycerides (>200 mg/dL) or fatty liver disease?

• If yes: tirzepatide's GIP effect improves lipid metabolism and liver fat more than semaglutide
• If no: this factor doesn't differentiate the two

Step 6: How long are you willing to titrate?

• If you want to reach maintenance dose faster: semaglutide (12-16 weeks vs 20 weeks for tirzepatide)
• If titration speed doesn't matter: either is fine

Most patients end up choosing based on step 1 (cost) or step 3 (weight loss priority). The other factors matter for specific subgroups but don't change the decision for the majority.

FAQ

Are Mounjaro and Ozempic the same medication? No. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, a GLP-1 receptor agonist only. They work through different mechanisms and are not interchangeable.

Which is better for weight loss, Mounjaro or Ozempic? Tirzepatide (Mounjaro/Zepbound) produces more weight loss. Head-to-head and indirect trial comparisons show tirzepatide produces 15 to 20% more weight loss than semaglutide at maximum doses. Tirzepatide 15 mg averaged 20.9% weight loss in SURMOUNT-1 vs 15% for semaglutide 2.4 mg in STEP 1.

Can I switch from Ozempic to Mounjaro? Yes. Switching is safe and common. Start tirzepatide at 2.5 mg regardless of your semaglutide dose, then titrate up. No washout period is needed. Inject the first tirzepatide dose the same week you would have taken your next semaglutide dose.

Which has worse side effects, Mounjaro or Ozempic? Semaglutide has higher nausea rates (44% vs 29% in obesity trials). Tirzepatide's dual mechanism appears to reduce nausea despite producing more weight loss. Both have similar rates of diarrhea, constipation, and rare serious events like pancreatitis.

Is Mounjaro stronger than Ozempic? "Stronger" isn't the right framing. Tirzepatide produces more weight loss and slightly better A1C reduction, but it works through a different mechanism, not a higher dose of the same mechanism. The GIP receptor activation changes the metabolic response in ways that aren't captured by "strength."

Do Mounjaro and Ozempic cost the same? Brand-name prices are similar: Ozempic costs $969/month, Mounjaro costs $1,023/month. Compounded versions differ more: compounded semaglutide costs $250-400/month, compounded tirzepatide costs $450-650/month. Insurance coverage varies widely.

Which works faster, Mounjaro or Ozempic? Both start working within the first week. Appetite suppression is noticeable within 24 to 48 hours of the first injection for both. Weight loss becomes measurable within 4 weeks. Tirzepatide produces faster weight loss in the first 12 weeks, but both require 6 to 12 months to reach maximum effect.

Can you take Mounjaro and Ozempic together? No. Combining two GLP-1 receptor agonists provides no additional benefit and increases side effects. Both medications activate the same GLP-1 receptor. Taking them together would be redundant and potentially dangerous.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and hasn't undergone the same manufacturing oversight. Potency and purity can vary between compounding pharmacies. Compounded tirzepatide is not interchangeable with brand-name Mounjaro.

Which is better for diabetes, Mounjaro or Ozempic? Both are highly effective. Tirzepatide reduces A1C slightly more in head-to-head trials (2.01% reduction vs 1.86% for semaglutide in SURPASS-2), but the difference is modest. Both reduce cardiovascular risk, though semaglutide has more published outcomes data.

Why does Mounjaro cause less nausea than Ozempic? GIP receptor activation appears to dampen the nausea signal from GLP-1 receptor activation. The mechanism isn't fully understood, but clinical trials consistently show lower nausea rates for tirzepatide despite higher weight loss. SURMOUNT-1 reported 29% nausea for tirzepatide vs 44% for semaglutide in STEP 1.

Can I use Mounjaro if Ozempic didn't work for me? Yes. If semaglutide produced inadequate weight loss or intolerable side effects, tirzepatide is worth trying. The dual mechanism often produces better results in patients who didn't respond well to semaglutide alone. About 60% of semaglutide non-responders see better outcomes on tirzepatide in clinical practice patterns.

Sources

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
8. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021.
9. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes: gastric emptying substudy. Diabetes Care. 2023.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1 - 7 trials. Diabetes & Metabolism. 2019.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. FDA Drug Shortages Database. Current and resolved drug shortages and discontinuations reported to FDA. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.